Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay

Area of Science:

• Oncology
• Microbiome Research
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) presents unique challenges, including resistance to EGFR tyrosine kinase inhibitors (TKIs) and treatment toxicities.
• The host microbiome is increasingly recognized for its potential impact on the efficacy and tolerability of EGFR-targeted therapies.

Purpose of the Study:

• To review the characteristics of the microbiome in EGFR-mutant NSCLC.
• To discuss the interaction between the gut, respiratory, and intratumoral microbiome and EGFR-TKI therapy.
• To explore strategies for enhancing TKI efficacy and immunotherapy sensitivity.

Main Methods:

• Literature review summarizing microbiome characteristics in EGFR-mutant NSCLC.
• Analysis of differential microbiome shifts associated with various TKIs.
• Exploration of preclinical and early clinical data on microbiota-targeted interventions.

Main Results:

• The microbiome plays a significant role in modulating responses to EGFR-TKIs in NSCLC.
• Specific microbiome compositions are associated with different TKI treatments.
• Microbiota-targeted interventions show potential for improving TKI efficacy and reducing toxicity.

Conclusions:

• Microbiome research in EGFR-mutant NSCLC offers substantial potential for refining therapeutic outcomes.
• Microbiota-targeted interventions could enhance TKI efficacy, mitigate toxicity, and potentially improve immunotherapy responses.
• Integrative studies combining microbiome, metabolome, and immune profiling are crucial for personalized clinical strategies.